Curis to Present at Upcoming 30th Annual SNO Meeting

Core Insights - Curis, Inc. is set to present clinical data on emavusertib (CA-4948), an IRAK4 inhibitor, at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 19-23, 2025 [1] Group 1: Clinical Data Presentations - The company will showcase three presentations on emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) [1] - A poster presentation on November 21, 2025, will feature Dr. Christian Grommes discussing the genetic mutation profile and CNS pharmacokinetics in relapsed/refractory PCNSL patients responding to emavusertib and BTKi combination [1] - Another poster presentation on the same day will be led by Dr. Lakshmi Nayak, focusing on the preliminary safety and efficacy of emavusertib in combination with Ibrutinib in relapsed/refractory PCNSL patients [1] Group 2: Presentation Formats and Details - The presentations will include both poster and rapid oral formats, with the rapid oral presentation scheduled for November 22, 2025, by Dr. Christian Grommes [1] - The rapid oral presentation will also analyze the genetic mutation profile and CNS pharmacokinetics in the same patient group [1]